Therapeutic silencing of KRAS using systemically delivered siRNAs

Chad V. Pecot, Sherry Y. Wu, Seth Bellister, Justyna Filant, Rajesha Rupaimoole, Takeshi Hisamatsu, Rajat Bhattacharya, Anshumaan Maharaj, Salma Azam, Cristian Rodriguez-Aguayo, Archana S. Nagaraja, Maria Pia Morelli, Kshipra M. Gharpure, Trent A. Waugh, Vianey Gonzalez-Villasana, Behrouz Zand, Heather J. Dalton, Scott Kopetz, Gabriel Lopez-Berestein, Lee M. Ellis & 1 others Anil K. Sood

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Despite being among the most common oncogenes in human cancer, to date, there are no effective clinical options for inhibiting KRAS activity. We investigated whether systemically delivered KRAS siRNAs have therapeutic potential in KRAS-mutated cancer models. We identified KRAS siRNA sequences with notable potency in knocking down KRAS expression. Using lung and colon adenocarcinoma cell lines, we assessed antiproliferative effects of KRAS silencing in vitro. For in vivo experiments, we used a nanoliposomal delivery platform, DOPC, for systemic delivery of siRNAs. Various lung and colon cancer models were used to determine efficacy of systemic KRAS siRNA based on tumor growth, development of metastasis, and downstream signaling. KRAS siRNA sequences induced >90% knockdown of KRAS expression, significantly reducing viability in mutant cell lines. In the lung cancer model, KRAS siRNA treatment demonstrated significant reductions in primary tumor growth and distant metastatic disease, while the addition of CDDP was not additive. Significant reductions in Ki-67 indices were seen in all treatment groups, whereas significant increases in caspase-3 activity were only seen in the CDDP treatment groups. In the colon cancer model, KRAS siRNA reduced tumor KRAS and pERK expression. KRAS siRNAs significantly reduced HCP1 subcutaneous tumor growth, as well as outgrowth of liver metastases. Our studies demonstrate a proof-of-concept approach to therapeutic KRAS targeting using nanoparticle delivery of siRNA. This study highlights the potential translational impact of therapeutic RNA interference, which may have broad applications in oncology, especially for traditional "undruggable" targets.

Original languageEnglish (US)
Pages (from-to)2876-2885
Number of pages10
JournalMolecular Cancer Therapeutics
Volume13
Issue number12
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Fingerprint

Small Interfering RNA
Neoplasms
Colonic Neoplasms
Lung Neoplasms
Therapeutics
Neoplasm Metastasis
Cell Line
Growth
RNA Interference
Growth and Development
Oncogenes
Caspase 3
Nanoparticles
Colon
Liver

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pecot, C. V., Wu, S. Y., Bellister, S., Filant, J., Rupaimoole, R., Hisamatsu, T., ... Sood, A. K. (2014). Therapeutic silencing of KRAS using systemically delivered siRNAs. Molecular Cancer Therapeutics, 13(12), 2876-2885. https://doi.org/10.1158/1535-7163.MCT-14-0074

Therapeutic silencing of KRAS using systemically delivered siRNAs. / Pecot, Chad V.; Wu, Sherry Y.; Bellister, Seth; Filant, Justyna; Rupaimoole, Rajesha; Hisamatsu, Takeshi; Bhattacharya, Rajat; Maharaj, Anshumaan; Azam, Salma; Rodriguez-Aguayo, Cristian; Nagaraja, Archana S.; Morelli, Maria Pia; Gharpure, Kshipra M.; Waugh, Trent A.; Gonzalez-Villasana, Vianey; Zand, Behrouz; Dalton, Heather J.; Kopetz, Scott; Lopez-Berestein, Gabriel; Ellis, Lee M.; Sood, Anil K.

In: Molecular Cancer Therapeutics, Vol. 13, No. 12, 01.12.2014, p. 2876-2885.

Research output: Contribution to journalArticle

Pecot, CV, Wu, SY, Bellister, S, Filant, J, Rupaimoole, R, Hisamatsu, T, Bhattacharya, R, Maharaj, A, Azam, S, Rodriguez-Aguayo, C, Nagaraja, AS, Morelli, MP, Gharpure, KM, Waugh, TA, Gonzalez-Villasana, V, Zand, B, Dalton, HJ, Kopetz, S, Lopez-Berestein, G, Ellis, LM & Sood, AK 2014, 'Therapeutic silencing of KRAS using systemically delivered siRNAs', Molecular Cancer Therapeutics, vol. 13, no. 12, pp. 2876-2885. https://doi.org/10.1158/1535-7163.MCT-14-0074
Pecot, Chad V. ; Wu, Sherry Y. ; Bellister, Seth ; Filant, Justyna ; Rupaimoole, Rajesha ; Hisamatsu, Takeshi ; Bhattacharya, Rajat ; Maharaj, Anshumaan ; Azam, Salma ; Rodriguez-Aguayo, Cristian ; Nagaraja, Archana S. ; Morelli, Maria Pia ; Gharpure, Kshipra M. ; Waugh, Trent A. ; Gonzalez-Villasana, Vianey ; Zand, Behrouz ; Dalton, Heather J. ; Kopetz, Scott ; Lopez-Berestein, Gabriel ; Ellis, Lee M. ; Sood, Anil K. / Therapeutic silencing of KRAS using systemically delivered siRNAs. In: Molecular Cancer Therapeutics. 2014 ; Vol. 13, No. 12. pp. 2876-2885.
@article{1ad8ce4ed6224a3b98ded532141a2f26,
title = "Therapeutic silencing of KRAS using systemically delivered siRNAs",
abstract = "Despite being among the most common oncogenes in human cancer, to date, there are no effective clinical options for inhibiting KRAS activity. We investigated whether systemically delivered KRAS siRNAs have therapeutic potential in KRAS-mutated cancer models. We identified KRAS siRNA sequences with notable potency in knocking down KRAS expression. Using lung and colon adenocarcinoma cell lines, we assessed antiproliferative effects of KRAS silencing in vitro. For in vivo experiments, we used a nanoliposomal delivery platform, DOPC, for systemic delivery of siRNAs. Various lung and colon cancer models were used to determine efficacy of systemic KRAS siRNA based on tumor growth, development of metastasis, and downstream signaling. KRAS siRNA sequences induced >90{\%} knockdown of KRAS expression, significantly reducing viability in mutant cell lines. In the lung cancer model, KRAS siRNA treatment demonstrated significant reductions in primary tumor growth and distant metastatic disease, while the addition of CDDP was not additive. Significant reductions in Ki-67 indices were seen in all treatment groups, whereas significant increases in caspase-3 activity were only seen in the CDDP treatment groups. In the colon cancer model, KRAS siRNA reduced tumor KRAS and pERK expression. KRAS siRNAs significantly reduced HCP1 subcutaneous tumor growth, as well as outgrowth of liver metastases. Our studies demonstrate a proof-of-concept approach to therapeutic KRAS targeting using nanoparticle delivery of siRNA. This study highlights the potential translational impact of therapeutic RNA interference, which may have broad applications in oncology, especially for traditional {"}undruggable{"} targets.",
author = "Pecot, {Chad V.} and Wu, {Sherry Y.} and Seth Bellister and Justyna Filant and Rajesha Rupaimoole and Takeshi Hisamatsu and Rajat Bhattacharya and Anshumaan Maharaj and Salma Azam and Cristian Rodriguez-Aguayo and Nagaraja, {Archana S.} and Morelli, {Maria Pia} and Gharpure, {Kshipra M.} and Waugh, {Trent A.} and Vianey Gonzalez-Villasana and Behrouz Zand and Dalton, {Heather J.} and Scott Kopetz and Gabriel Lopez-Berestein and Ellis, {Lee M.} and Sood, {Anil K.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1158/1535-7163.MCT-14-0074",
language = "English (US)",
volume = "13",
pages = "2876--2885",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Therapeutic silencing of KRAS using systemically delivered siRNAs

AU - Pecot, Chad V.

AU - Wu, Sherry Y.

AU - Bellister, Seth

AU - Filant, Justyna

AU - Rupaimoole, Rajesha

AU - Hisamatsu, Takeshi

AU - Bhattacharya, Rajat

AU - Maharaj, Anshumaan

AU - Azam, Salma

AU - Rodriguez-Aguayo, Cristian

AU - Nagaraja, Archana S.

AU - Morelli, Maria Pia

AU - Gharpure, Kshipra M.

AU - Waugh, Trent A.

AU - Gonzalez-Villasana, Vianey

AU - Zand, Behrouz

AU - Dalton, Heather J.

AU - Kopetz, Scott

AU - Lopez-Berestein, Gabriel

AU - Ellis, Lee M.

AU - Sood, Anil K.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Despite being among the most common oncogenes in human cancer, to date, there are no effective clinical options for inhibiting KRAS activity. We investigated whether systemically delivered KRAS siRNAs have therapeutic potential in KRAS-mutated cancer models. We identified KRAS siRNA sequences with notable potency in knocking down KRAS expression. Using lung and colon adenocarcinoma cell lines, we assessed antiproliferative effects of KRAS silencing in vitro. For in vivo experiments, we used a nanoliposomal delivery platform, DOPC, for systemic delivery of siRNAs. Various lung and colon cancer models were used to determine efficacy of systemic KRAS siRNA based on tumor growth, development of metastasis, and downstream signaling. KRAS siRNA sequences induced >90% knockdown of KRAS expression, significantly reducing viability in mutant cell lines. In the lung cancer model, KRAS siRNA treatment demonstrated significant reductions in primary tumor growth and distant metastatic disease, while the addition of CDDP was not additive. Significant reductions in Ki-67 indices were seen in all treatment groups, whereas significant increases in caspase-3 activity were only seen in the CDDP treatment groups. In the colon cancer model, KRAS siRNA reduced tumor KRAS and pERK expression. KRAS siRNAs significantly reduced HCP1 subcutaneous tumor growth, as well as outgrowth of liver metastases. Our studies demonstrate a proof-of-concept approach to therapeutic KRAS targeting using nanoparticle delivery of siRNA. This study highlights the potential translational impact of therapeutic RNA interference, which may have broad applications in oncology, especially for traditional "undruggable" targets.

AB - Despite being among the most common oncogenes in human cancer, to date, there are no effective clinical options for inhibiting KRAS activity. We investigated whether systemically delivered KRAS siRNAs have therapeutic potential in KRAS-mutated cancer models. We identified KRAS siRNA sequences with notable potency in knocking down KRAS expression. Using lung and colon adenocarcinoma cell lines, we assessed antiproliferative effects of KRAS silencing in vitro. For in vivo experiments, we used a nanoliposomal delivery platform, DOPC, for systemic delivery of siRNAs. Various lung and colon cancer models were used to determine efficacy of systemic KRAS siRNA based on tumor growth, development of metastasis, and downstream signaling. KRAS siRNA sequences induced >90% knockdown of KRAS expression, significantly reducing viability in mutant cell lines. In the lung cancer model, KRAS siRNA treatment demonstrated significant reductions in primary tumor growth and distant metastatic disease, while the addition of CDDP was not additive. Significant reductions in Ki-67 indices were seen in all treatment groups, whereas significant increases in caspase-3 activity were only seen in the CDDP treatment groups. In the colon cancer model, KRAS siRNA reduced tumor KRAS and pERK expression. KRAS siRNAs significantly reduced HCP1 subcutaneous tumor growth, as well as outgrowth of liver metastases. Our studies demonstrate a proof-of-concept approach to therapeutic KRAS targeting using nanoparticle delivery of siRNA. This study highlights the potential translational impact of therapeutic RNA interference, which may have broad applications in oncology, especially for traditional "undruggable" targets.

UR - http://www.scopus.com/inward/record.url?scp=84918495709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918495709&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-14-0074

DO - 10.1158/1535-7163.MCT-14-0074

M3 - Article

VL - 13

SP - 2876

EP - 2885

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 12

ER -